Abstract: A non-transitory computer readable medium, a system, and a method for displaying a remote browser isolation (RBI) configuration window are disclosed. In an embodiment, a non-transitory computer readable medium includes instructions to be executed in a computer system, where the instructions when executed in the computer system perform a method comprising displaying an RBI configuration window, displaying an on/off activation feature within the RBI configuration window, and displaying an RBI profile selection menu within the RBI configuration window, where the RBI profile selection menu includes a plurality of spatially grouped sets that include an RBI profile selector, RBI profile identifier text, and selectable RBI protected browsing action icons that indicate to a user whether a corresponding RBI protected browsing action is included in an RBI policy.

Abstract: A non-transitory computer readable medium, a system, and a method for displaying a remote browser isolation (RBI) configuration window are disclosed. In an embodiment, a non-transitory computer readable medium includes instructions to be executed in a computer system, where the instructions when executed in the computer system perform a method comprising displaying an RBI configuration window, displaying an on/off activation feature within the RBI configuration window, and displaying an RBI profile selection menu within the RBI configuration window, where the RBI profile selection menu includes a plurality of spatially grouped sets that include an RBI profile selector, RBI profile identifier text, and selectable RBI protected browsing action icons that indicate to a user whether a corresponding RBI protected browsing action is included in an RBI policy.

Abstract: The invention relates to superantigen mediated expansion of antigen-specific T cells for cancer and infectious agent treatment/prophylaxis. Mice were injected with inactivated B16F10 mouse melanoma cells, followed by injection with a combined SEA/SEB injection or a sham injection on days 3 and 6, followed by day 4 challenge with live melanoma cells. The SEA/SEB recipient mice survived longer post-challenge and had a higher CTLs against tumor cells than did the sham injected mice. SEA/SEB TCR activation has been reported to be independent of antigen specificity of TCRs. This invention provides a method whereby a combination of Staphylococcal enterotoxin superantigens is used to enhance specific immune responses to activating antigens to enhance immune responses against cancers and infectious agents.

Abstract: The invention relates to superantigen mediated expansion of antigen-specific T cells for cancer and infectious agent treatment/prophylaxis. Mice were injected with inactivated B16F10 mouse melanoma cells, followed by injection with a combined SEA/SEB injection or a sham injection on days 3 and 6, followed by day 4 challenge with live melanoma cells. The SEA/SEB recipient mice survived longer post-challenge and had a higher CTLs against tumor cells than did the sham injected mice. SEA/SEB TCR activation has been reported to be independent of antigen specificity of TCRs. This invention provides a method whereby a combination of Staphylococcal enterotoxin superantigens is used to enhance specific immune responses to activating antigens to enhance immune responses against cancers and infectious agents.

Abstract: The human immunodeficiency virus (HIV) contains, in addition to the canonical genes gag, pol, and env, an open reading frame in the 3' region of the genome that overlaps with the 3' long terminal repeat (LTR). Initial studies on the protein encoded by this ORF revealed a negative effect on HIV replication in vitro and this gene product was subsequently designated the negative factor, or Nef. The nef gene product is 25-29 kDa protein that localizes primarily to the cytoplasm of HIV-infected cells. The subject of this invention pertains to the discovery of a superantigen activity associated with this peptide and peptidic fragments derived therefrom. Superantigens are powerful T-cell mitogens that bind directly to major histocompatibility complex (MHC) class II molecules and form a binary complex with the variable .beta. (V.sub..beta.) region of the T-cell antigen receptor (TCR).

Abstract: The subject invention concerns novel superantigen proteins and peptides and methods of use of these superantigens. Specifically exemplified are peptide agonists from mouse mammary tumor virus, feline immunodeficiency virus and human immunodeficiency virus. The peptides can also be used to produce, purify and detect antibodies that bind to superantigens. These superantigens and their corresponding peptides can be used in both diagnostic and therapeutic protocols.

Abstract: The invention concerns novel AVP-binding peptides having the formula:Thr-Met-X-Val-Leu-Thr-Gly-Ser-Pro-Bwherein X is selected from the group consisting of Lys, Arg, and Asp; B is OH, NH.sub.2, NHAlK, wherein Alk is lower alkyl of 1-4 carbons, inclusive. These peptides block AVP function, and, therefore, are useful in many areas among which is the control of hypertension.

Abstract: The invention concerns novel AVP-binding peptides having the formula:Thr-Met-X-Val-Leu-Thr-Gly-Ser-Pro-Bwherein X is selected from the group consisting of Lys, Arg, and Asp; B is OH, NH.sub.2, NHAlk, wherein Alk is lower alkyl of 1-4 carbons, inclusive. These peptides block AVP function, and, therefore, are useful in many areas among which is the control of hypertension.